Regulation of MHC class II gene expression by the class II transactivator

Nature Reviews Immunology

Volumn 5, Issue 10, 2005, Pages 793-806

  Reith, Walter ^a   LeibundGut Landmann, Salomé ^a,b   Waldburger, Jean Marc ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

AUTOIMMUNE DISEASE; CANCER THERAPY; CLINICAL TRIAL; GENE EXPRESSION; GENE INDUCTION; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; VIRUS INFECTION;

ANIMALS; GENE EXPRESSION REGULATION; GENES, MHC CLASS II; HUMANS; MICE; MODELS, IMMUNOLOGICAL; NUCLEAR PROTEINS; TRANS-ACTIVATORS;

EID: 25844499012     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1708     Document Type: Review

References (140)

1. Klein, C., Lisowska-Grospierre, B., LeDeist, F., Fischer, A. & Griscelli, C. Major histocompatibility complex class II deficiency: clinical manifestations, immunologic features, and outcome. J. Pediatr. 123, 921-928 (1993).
2. Reith, W. & Mach, B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu. Rev. Immunol. 19, 331-373 (2001).
3. Chang, C. H., Guerder, S., Hong, S. C., van Ewijk, W. & Flavell, R. A. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity 4, 167-178 (1996). This paper, together with reference 5, describes the generation of C2ta-knockout mice, which have a global loss of MHC class II expression, thereby reproducing the phenotype of patients with BLS.
4. Clausen, B. E. et al. Residual MHC class II expression on mature dendritic cells and activated B cells in RFX5-deficient mice. Immunity 8, 143-155 (1998).
5. Itoh-Lindstrom, Y. et al. Reduced IL-4-, lipopolysaccharide-, and IFN-γ-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain. J. Immunol. 163, 2425-2431 (1999).
6. LeibundGut-Landmann, S., Waldburger, J. M., Reis e Sousa, C., Acha-Orbea, H. & Reith, W. MHC class II expression is differentially regulated in plasmacytoid and conventional dendritic cells. Nature Immunol. 5, 899-908 (2004). This paper describes the generation of mice that lack pIII and pIV of the C2ta gene and shows that pDCs differ from all other DC subsets with respect to C2ta promoter usage. The results define pI as a myeloid-cell-specific promoter and pIII as a lymphoid-cell-specific promoter.
7. Waldburger, J. M., Suter, T., Fontana, A., Acha-Orbea, H. & Reith, W. Selective abrogation of major histocompatibility complex class II expression on extrahematopoietic cells in mice lacking promoter IV of the class II transactivator gene. J. Exp. Med. 194, 393-406 (2001). This paper describes the generation of mice that lack pIV of the C2ta gene. It shows that this promoter is essential for driving IFN-γ-induced CIITA and MHC class II expression by non-haematopoietic cells but is dispensable for this function in macrophages.
8. Ting, J. P. & Trowsdale, J. Genetic control of MHC class II expression. Cell 109, S21-S33 (2002).
9. Boss, J. M. & Jensen, P. E. Transcriptional regulation of the MHC class II antigen presentation pathway. Curr. Opin. Immunol. 15, 105-111 (2003).
10. LeibundGut-Landmann, S. et al. Specificity and expression of CIITA, the master regulator of MHCII genes. Eur. J. Immunol. 34, 1513-1525 (2004).
11. Krawczyk, M. et al. Long distance control of MHC class II expression by multiple distal enhancers regulated by regulatory factor X complex and CIITA. J. Immunol. 173, 6200-6210 (2004).
12. Masternak, K., Peyraud, N., Krawczyk, M., Barras, E. & Reith, W. Chromatin remodeling and extragenic transcription at the MHC class II locus control region. Nature Immunol. 4, 132-137 (2003). References 11 and 12 show that CIITA is recruited not only to MHC class II promoters but also to multiple distant enhancers that are scattered throughout the MHC class II locus. One of these is situated in a locus control region that is found upstream of the HLA-DRA gene.
13. Accolla, R. S. Human B cell variants immunoselected against a single la antigen subset have lost expression in several la antigen subsets. J. Exp. Med. 157, 1053-1058 (1983).
14. Accolla, R. S. et al. alr-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression. J. Exp. Med. 164, 369-374 (1986).
15. - cell lines and in patients with BLS who are classified in complementation group A.
16. Steimle, V. et al. A novel DNA binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev. 9, 1021-1032 (1995).
17. Masternak, K. et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nature Genet. 20, 273-277 (1998).
18. Durand, B. et al. RFXAR a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J. 16, 1045-1055 (1997).
19. Nagarajan, U. M. et al. RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency. Immunity 10, 153-162 (1999). References 16-19 describe isolation of the genes encoding the RFXANK, RFX5 and RFXAP subunits of the RFX complex. They also show that these genes are mutated in patients with BLS who are classified in complementation group B, C and D, respectively.
20. Reith, W. et al. Congenital immunodeficiency with a regulatory defect in MHC class II gene expression lacks a specific HLA-DR promoter binding protein, RF-X. Cell 53, 897-906 (1988).
21. Moreno, C. S., Beresford, G. W., Louis-Plence, P., Morris, A. C. & Boss, J. M. CREB regulates MHC class II expression in a CIITA-dependent manner. Immunity 10, 143-151 (1999).
22. Mantovani, R. The molecular biology of the CCAAT-binding factor NF-Y. Gene 239, 15-27 (1999).
23. Muhlethaler-Mottet, A. et al. The S box of major histocompatibility complex class II promoters is a key determinant for recruitment of the transcriptional co-activator CIITA. J. Biol. Chem. 279, 40529-40535 (2004).
24. Masternak, K. et al. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev. 14, 1156-1166 (2000). This paper was the first to show that CIITA is physically recruited to the promoters of its target genes in vivo and in vitro through multiple protein-protein interactions with an enhanceosome complex formed by DNA-bound transcription factors.
25. Zika, E. & Ting, J. P. Epigenetic control of MHC class II: interplay between CIITA and histone-modifying enzymes. Curr. Opin. Immunol. 17, 58-64 (2005).
26. Ting, J. P. & Davis, B. K. CATERPILLER: a novel gene family important in immunity, cell death, and diseases. Annu. Rev. Immunol. 23, 387-414 (2005).
27. Inohara, N., Chamaillard, M., McDonald, C. & Nunez, G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu. Rev. Biochem. 74, 355-383 (2005).
28. Fontes, J. D., Jiang, B. & Peterlin, B. M. The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32. Nucleic Acids Res. 25, 2522-2528 (1997).
29. Mahanta, S. K., Scholl, T., Yang, F. C. & Strominger, J. L. Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. Proc. Natl Acad. Sci. USA 94, 6324-6329 (1997).
30. Spilianakis, C. et al. CIITA regulates transcription onset via Ser5-phosphorylation of RNA Pol II. EMBO J. 22, 5125-5136 (2003).
31. Kanazawa, S., Okamoto, T. & Peterlin, B. M. Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection. Immunity 12, 61-70 (2000).
32. Mudhasani, R. & Fontes, J. D. The class II transactivator requires brahma-related gene 1 to activate transcription of major histocompatibility complex class II genes. Mol. Cell. Biol. 22, 5019-5026 (2002).
33. II.250. Mol. Cell 7, 105-115 (2001).
34. Tosi, G., Jabrane-Ferrat, N. & Peterlin, B. M. Phosphorylation of CIITA directs its oligomerization, accumulation and increased activity on MHCII promoters. EMBO J. 21, 5467-5476 (2002).
35. Sisk, T. J., Nickerson, K., Kwok, R. P. & Chang, C. H. Phosphorylation of class II transactivator regulates its interaction ability and transactivation function. Int. Immunol. 15, 1195-1205 (2003).
36. Greer, S. F. et al. Serine residues 286, 288, and 293 within the CIITA: a mechanism for down-regulating CIITA activity through phosphorylation. J. Immunol. 173, 376-383 (2004).
37. Greer, S. F., Zika, E., Conti, B., Zhu, X. S. & Ting, J. P. Enhancement of CIITA transcriptional function by ubiquitin. Nature Immunol. 4, 1074-1082 (2003).
38. + T cells, because it is required for the induction of CIITA and MHC class II expression in TECs.
39. Steimle, V., Siegrist, C.-A., Mottet, A., Lisowska-Grospierre, B. & Mach, B. Regulation of MHC class II expression by interferon-γ mediated by the transactivator gene CIITA. Science 265, 106-109 (1994). This seminal paper was the first to show that IFN-γ-induced MHC class II expression is mediated by the induction of CIITA expression.
40. Dong, Y., Rohn, W. M. & Benveniste, E. N. IFN-γ regulation of the type IV class II transactivator promoter in astrocytes. J. Immunol. 162, 4731-4739 (1999).
41. Muhlethaler-Mottet, A., Di Berardino, W., Otten, L. A. & Mach, B. Activation of the MHC class II transactivator CIITA by interferon-γ requires cooperative interaction between Stat1 and USF-1. Immunity 8, 157-166 (1998). This paper was the first detailed description of the molecular mechanisms that mediate the IFN-γ induction of pIV of CIITA.
42. Muhlethaler-Mottet, A., Otten, L. A., Steimle, V. & Mach, B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. 16, 2851-2860 (1997). This key paper was the first to describe how multiple promoters with different functions drive transcription of the gene encoding CIITA.
43. van den Elsen, P. J. et al. Lack of CIITA expression is central to the absence of antigen presentation functions of trophoblast cells and is caused by methylation of the IFN-γ inducible promoter (PIV) of CIITA. Hum. Immunol. 61, 850-862 (2000).
44. Morris, A. C., Spangler, W. E. & Boss, J. M. Methylation of class II trans-activator promoter IV: a novel mechanism of MHC class II gene control. J. Immunol. 164, 4143-4149 (2000). References 43 and 44 report that the gene encoding CIITA is irreversibly silenced in trophoblasts by DNA methylation of pIV.
45. Silacci, P., Mottet, A., Steimle, V., Reith, W. & Mach, B. Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA. J. Exp. Med. 180, 1329-1336 (1994).
46. Sartoris, S., Tosi, G., De Lerma, B., Cestari, T. & Accolla, R. S. Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells. Eur. J. Immunol. 26, 2456-2460 (1996).
47. Landmann, S. et al. Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class II transactivator (CIITA) expression. J. Exp. Med. 194, 379-392 (2001).
48. Holling, T. M., Schooten, E., Langerak, A. W. & van den Elsen, P. J. Regulation of MHC class II expression in human T-cell malignancies. Blood 103, 1438-1444 (2004).
49. Murphy, S. P., Holtz, R., Lewandowski, N., Tomasi, T. B. & Fuji, H. DNA alkylating agents alleviate silencing of class II transactivator gene expression in L1210 lymphoma cells. J. Immunol. 169, 3085-3093 (2002).
50. van der Stoep, N., Biesta, P., Quinten, E. & van den Elsen, P. J. Lack of IFN-γ-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines. Int. J. Cancer 97, 501-507 (2002).
51. Lee, Y. J. et al. TGF-β suppresses IFN-γ induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J. Immunol. 158, 2065-2075 (1997).
52. Rohn, W., Tang, L. P., Dong, Y. & Benveniste, E. N. IL-1β inhibits IFN-γ-induced class II MHC expression by suppressing transcription of the class II transactivator gene. J. Immunol. 162, 886-896 (1999).
53. O'Keefe, G. M., Nguyen, V. T. & Benveniste, E. N. Class II transactivator and class II MHC gene expression in microglia: modulation by the cytokines TGF-β, IL-4, IL-13 and IL-10. Eur. J. Immunol. 29, 1275-1285 (1999).
54. Navarrete, S. A., Kehlen, A., Schutte, W., Langner, J. & Riemann, D. Regulation by transforming growth factor-β1 of class II mRNA and protein expression in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Int. Immunol. 10, 601-607 (1998).
55. Dong, Y., Tang, L., Letterio, J. J. & Benveniste, E. N. The Smad3 protein is involved in TGF-β inhibition of class II transactivator and class II MHC expression. J. Immunol. 167, 311-319 (2001).
56. Okamoto, H., Asamitsu, K., Nishimura, H., Kamatani, N. & Okamoto, T. Reciprocal modulation of transcriptional activities between HIV-1 Tat and MHC class II transactivator CIITA. Biochem. Biophys. Res. Commun. 279, 494-499 (2000).
57. Abendroth, A. et al. Modulation of major histocompatibility class II protein expression by varicella-zoster virus. J. Virol. 74, 1900-1907 (2000).
58. + T-cell response is mediated by repression of γ interferon-induced class II transactivator expression. J. Virol. 73, 6582-6589 (1999).
59. Miller, D. M. et al. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J. Exp. Med. 187, 675-683 (1998).
60. Gao, J. et al. Human parainfluenza virus type 3 inhibits γ interferon-induced major histocompatibility complex class II expression directly and by inducing α/β interferon. J. Virol. 75, 1124-1131 (2001).
61. Zhong, G., Fan, T. & Liu, L. Chlamydia inhibits interferon γ-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1. J. Exp. Med. 189, 1931-1938 (1999).
62. Luder, C. G. et al. Toxoplasma gondii inhibits MHC class II expression in neural antigen-presenting cells by down-regulating the class II transactivator CIITA. J. Neuroimmunol. 134, 12-24 (2003).
63. Pai, R. K., Convery, M., Hamilton, T. A., Boom, W. H. & Harding, C. V. Inhibition of IFN-γ-induced class II transactivator expression by a 19-kDa lipoprotein from Mycobacterium tuberculosis: a potential mechanism for immune evasion. J. Immunol. 171, 175-184 (2003).
64. Wojciechowski, W., DeSanctis, J., Skamene, E. & Radzioch, D. Attenuation of MHC class II expression in macrophages infected with Mycobacterium bovis bacillus Calmette-Guerin involves class II transactivator and depends on the Nramp1 gene. J. Immunol. 163, 2688-2696 (1999).
65. Kwak, B., Mulhaupt, F., Myit, S. & Mach, F. Statins as a newly recognized type of immunomodulator. Nature Med. 6, 1399-1402 (2000).
66. H2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420, 78-84 (2002).
67. De Lerma, B. A., Procopio, F. A., Mortara, L., Tosi, G. & Accolla, R. S. The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in myelomonocytic cells. Eur. J. Immunol. 35, 603-611 (2005).
68. Schnappauf, F. et al. N-terminal destruction signals lead to rapid degradation of the major histocompatibility complex class II transactivator CIITA. Eur. J. Immunol. 33, 2337-2347 (2003).
69. Nickerson, K. et al. Dendritic cell-specific MHC class II transactivator contains a caspase recruitment domain that confers potent transactivation activity. J. Biol. Chem. 276, 19089-19093 (2001).
70. Deffrennes, V. et al. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter. J. Immunol. 167, 98-106 (2001).
71. Goodwin, B. L. et al. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. Cell Growth Differ. 12, 327-335 (2001).
72. Piskurich, J. F., Linhoff, M. W., Wang, Y. & Ting, J. P. Two distinct γ interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor β. Mol. Cell. Biol. 19, 431-440 (1999). This paper shows that pIII of the human CIITA gene can be induced by IFN-γ through a STAT1-dependent enhancer that is situated 5 kb upstream.
73. Suter, T. et al. Dendritic cells and differential usage of the MHC class II transactivator promoters in the central nervous system in experimental autoimmune encephalitis. Eur. J. Immunol. 30, 794-802 (2000).
74. Pai, R. K., Askew, D., Boom, W. H. & Harding, C. V. Regulation of class II MHC expression in APCs: roles of types I, III, and IV class II transactivator. J. Immunol. 169, 1326-1333 (2002). Together with reference 6, this detailed kinetic study of CIITA expression shows that transcription from pI is sustained in IFN-γ-stimulated macrophages, whereas pIV is induced only transiently.
75. O'Keefe, G. M., Nguyen, V. T., Ping Tang, L. L. & Benveniste, R. N. IFN-γ regulation of class II transactivator promoter IV in macrophages and microglia: involvement of the suppressors of cytokine signaling-1 protein. J. Immunol. 166, 2260-2269 (2001).
76. Nikcevich, K. M., Piskurich, J. F., Hellendall, R. P., Wang, Y. & Ting, J. P. Differential selectivity of CIITA promoter activation by IRN-γ and IRF-1 in astrocytes and macrophages: CIITA promoter activation is not affected by TNF-α. J. Neuroimmunol. 99, 195-204 (1999).
77. Starr, T. K., Jameson, S. C. & Hogquist, K. A. Positive and negative selection of T cells. Annu. Rev. Immunol. 21, 139-176 (2003).
78. Martinic, M. M. et al. Efficient T cell repertoire selection in tetraparental chimeric mice independent of thymic epithelial MHC. Proc. Natl Acad. Sci. USA 100, 1861-1866 (2003).
79. Xi, H. et al. Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) type IV promoter by interferon regulatory factors 1 and 2. Oncogene 18, 5889-5903 (1999).
80. Xi, H., Goodwin, B., Shepherd, A. T. & Blanck, G. Impaired class II transactivator expression in mice lacking interferon regulatory factor-2. Oncogene 20, 4219-4227 (2001).
81. Morris, A. C., Beresford, G. W., Mooney, M. R. & Boss, J. M. Kinetics of a γ interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation. Mol. Cell. Biol. 22, 4781-4791 (2002). This paper reports a detailed time course of the events that lead to the activation of pIV by IFN-γ.
82. Takeuchi, O. et al. Differential usage of class II transactivator promoters PI and PIV during inflammation and injury in kidney. J. Am. Soc. Nephrol. 14, 2823-2832 (2003).
83. Pattenden, S. G., Klose, R., Karaskov, E. & Bremner, R. Interferon-γ-induced chromatin remodeling at the CIITA locus is BRG1 dependent. EMBO J. 21, 1978-1986 (2002).
84. Holtz, R., Choi, J. C., Petroff, M. G., Piskurich, J. F. & Murphy, S. P. Class II transactivator (CIITA) promoter methylation does not correlate with silencing of CIITA transcription in trophoblasts. Biol. Reprod. 69, 915-924 (2003).
85. Murphy, S. P., Choi, J. C. & Holtz, R. Regulation of major histocompatibility complex class II gene expression in trophoblast cells. Reprod. Biol. Endocrinol. 2, 52 (2004).
86. Anderson, G., Jenkinson, E. J., Moore, N. C. & Owen, J. J. MHC class II-positive epithelium and mesenchyme cells are both required for T-cell development in the thymus. Nature 362, 70-73 (1993).
87. Anderson, G. & Jenkinson, E. J. Lymphostromal interactions in thymic development and function. Nature Rev. Immunol. 1, 31-40 (2001).
88. Anderson, G., Hare, K. J., Platt, N. & Jenkinson, E. J. Discrimination between maintenance- and differentiation-inducing signals during initial and intermediate stages of positive selection. Eur. J. Immunol. 27, 1838-1842 (1997).
89. Honey, K. & Rudensky, A. The pIV-otal class II transactivator promoter regulates major histocompatibility complex class II expression in the thymus. J. Exp. Med. 194, F15-F18 (2001).
90. Rigaud, G. et al. Induction of CIITA and modification of In vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-γ: similarities and distinctions with respect to HLA-DR-constitutive B cells. J. Immunol. 156, 4254-4258 (1996).
91. Hare, K. J., Jenkinson, E. J. & Anderson, G. In vitro models of T cell development. Semin. Immunol. 11, 3-12 (1999).
92. Dalton, D. K. et al. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science 259, 1739-1742 (1993).
93. Huang, S. et al. Immune response in mice that lack the interferon-γ receptor. Science 259, 1742-1745 (1993).
94. Gill, J. et al. Thymic generation and regeneration. Immunol. Rev. 195, 28-50 (2003).
95. Lennon, A. M. et al. Isolation of a B-cell-specific promoter for the human class II transactivator. Immunogenetics 45, 266-273 (1997).
96. Colonna, M., Trinchieri, G. & Liu, Y. J. Plasmacytoid dendritic cells in immunity. Nature Immunol. 5, 1219-1226 (2004).
97. + T lymphocytes. J. Immunol. 170, 1150-1157 (2003).
98. Holling, T. M., van der Stoep, N., Quinten, E. & van den Elsen, P. J. Activated human T cells accomplish MHC class II expression through T cell-specific occupation of class II transactivator promoter III. J. Immunol. 168, 763-770 (2002).
99. Wong, A. W. et al. Regulation and specificity of MHC2TA promoter usage in human primary T lymphocytes and cell line. J. Immunol. 169, 3112-3119 (2002). References 98 and 99 establish that pIII of the CIITA gene drives CIITA and MHC class II expression by human T cells.
100. Ghosh, N. et al. A novel element and a TEF-2-like element activate the major histocompatibility complex class II transactivator in B-lymphocytes. J. Biol. Chem. 274, 32342-32350 (1999).
101. van der Stoep, N., Quinten, E. & van den Elsen, P. J. Transcriptional regulation of the MHC class II transactivator (CIITA) promoter III: identification of a novel regulatory region in the 5′-untranslated region and an important role for cAMP-responsive element binding protein 1 and activating transcription factor-1 in CIITA-promoter III transcriptional activation in B lymphocytes. J. Immunol. 169, 5061-5071 (2002).
102. van der Stoep, N., Quinten, E., Marcondes, R. M. & van den Elsen, P. J. E47, IRF-4, and PU.1 synergize to induce B-cell-specific activation of the class II transactivator promoter III (CIITA-PIII). Blood 104, 2849-2857 (2004). This paper shows that the B-cell-specific activity of pIII of the CIITA gene can be attributed to binding of the transcription factors E47, IRF4and PU.1.
103. Swanberg, M. et al. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nature Genet. 37, 486-494 (2005).
104. Piskurich, J. F. et al. BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nature Immunol. 1, 526-532 (2000).
105. Ghosh, N., Gyory, I., Wright, G., Wood, J. & Wright, K. L. Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells. J. Biol. Chem. 276, 15264-15268 (2001).
106. Accolla, R. S., Mazza, S., De Lerma, B. A., De, M. A. & Tosi, G. The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication. Eur. J. Immunol. 32, 2783-2791 (2002).
107. Casoli, C. et al. The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2. Blood 103, 995-1001 (2004).
108. Garcia-Lora, A., Algarra, I., Collado, A. & Garrido, F. Tumour immunology, vaccination and escape strategies. Eur. J. Immunogenet. 30, 177-183 (2003).
109. Toes, R. E., Schoenberger, S. P., van der Voort, E. I., Offringa, R. & Melief, C. J. CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin. Immunol. 10, 443-448 (1998).
110. Liu, A. et al. Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells. Hematol. Oncol. 17, 149-160 (1999).
111. Momburg, F., Herrmann, B., Moldenhauer, G. & Moller, P. B-cell lymphomas of high-grade malignancy frequently lack HLA-DR, -DP and -DQ antigens and associated invariant chain. Int. J. Cancer 40, 598-603 (1987).
112. Rimsza, L. M. et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 103, 4251-4258 (2004).
113. Fuji, H. & Iribe, H. Clonal variation in tumorigenicity of L1210 lymphoma cells: nontumorigenic variants with an enhanced expression of tumor-associated antigen and la antigens. Cancer Res. 46, 5541-5547 (1986).
114. Altomonte, M., Fonsatti, E., Visintin, A. & Maio, M. Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach? Oncogene 22, 6564-6569 (2003).
115. Morimoto, Y. et al. Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-γ in haematopoietic tumour cells. Br. J. Cancer 90, 844-852 (2004).
116. Cook, G. & Campbell, J. D. Immune regulation in multiple myeloma: the host-tumour conflict. Blood Rev. 13, 151-162 (1999).
117. Takamura, Y. et al. Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA). Glia 45, 392-405 (2004).
118. Guardiola, J. & Maffei, A. Control of MHC class II gene expression in autoimmune, infectious, and neoplastic diseases. Crit. Rev. Immunol. 13, 247-268 (1993).
119. Li, S., Kurts, C., Kontgen, F., Holdsworth, S. R. & Tipping, P. G. Major histocompatibility complex class II expression by intrinsic renal cells is required for crescentic glomerulonephritis. J. Exp. Med. 188, 597-602 (1998). This paper provides convincing evidence that MHC class II expression in renal tissues is required for the development of experimental glomerulonephritis in mice.
120. Leung, B. P. et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J. Immunol. 170, 1524-1530 (2003).
121. Palmer, G. et al. Assessment of the efficacy of different statins in murine collagen-induced arthritis. Arthritis Rheum. 50, 4051-4059 (2004).
122. McCarey, D. W. et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363, 2015-2021 (2004).
123. Kuipers, H. F. & van den Elsen, P. J. Statins and control of MHC2TA gene transcription. Nature Med. 11, 365-366 (2005).
124. Martin, B. K., Frelinger, J. G. & Ting, J. P. Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth. J. Immunol. 162, 6663-6670 (1999).
125. Meazza, R., Comes, A., Orengo, A. M., Ferrini, S. & Accolla, R. S. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. Eur. J. Immunol. 33, 1183-1192 (2003).
126. - phenotype after adenoviral delivery of both an expressible gene for MHC class II inducer and an antisense Ii-RNA construct in tumor cells. Gene Ther. 10, 1512-1518 (2003).
127. + tumor cells. J. Immunol. 149, 2391-2396 (1992).
128. Dissanayake, S. K., Tuera, N. & Ostrand-Rosenberg, S. Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome. J. Immunol. 174, 1811-1819 (2005).
129. Wang, Y. et al. Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii protein. Hum. Gene Ther. 16, 187-199 (2005). This paper describes a mouse model of prostate cancer in which 50% of the mice were cured by combining radiotherapy with gene therapy using CIITA, IFN-γ and IL-2 expression vectors, together with an antisense construct directed towards Ii mRNA. Moreover, 100% of cured animals were resistant to rechallenge with tumour cells.
130. Nagy, Z. A. et al. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nature Med. 8, 801-807 (2002).
131. Dechant, M., Bruenke, J. & Valerius, T. HLA class II antibodies in the treatment of hematologic malignancies. Semin. Oncol. 30, 465-475 (2003).
132. Martin, B. K. et al. Induction of MHC class I expression by the MHC class II transactivator CIITA. Immunity 6, 591-600 (1997).
133. Gobin, S. J., Peijnenburg, A., Keijsers, V. & van den Elsen, P. J. Site α is crucial for two routes of IFN γ-induced MHC class I transactivation: the ISRE-mediated route and a novel pathway involving CIITA. Immunity 6, 601-611 (1997).
134. Wong, A. W. et al. CIITA-regulated plexin-A1 affects T-cell-dendritic cell interactions. Nature Immunol. 4, 891-898 (2003).
135. Nagarajan, U. M., Bushey, A. & Boss, J. M. Modulation of gene expression by the MHC class II transactivator. J. Immunol. 169, 5078-5088 (2002).
136. 2(I) and other promoters. Mol. Cell. Biol. 21, 7078-7088 (2001).
137. Yee, C. S. et al. Cathepsin E: a novel target for regulation by class II transactivator. J. Immunol. 172, 5528-5534 (2004).
138. Gourley, T. S., Patel, D. R., Nickerson, K., Hong, S. C. & Chang, C. H. Aberrant expression of Fas ligand in mice deficient for the MHC class II transactivator. J. Immunol. 168, 4414-4419 (2002).
139. Sisk, T. J., Gourley, T., Roys, S. & Chang, C. H. MHC class II transactivator inhibits IL-4 gene transcription by competing with NF-AT to bind the coactivator CREB binding protein (CBP)/p300. J. Immunol. 165, 2511-2517 (2000).
140. H1 immunity. Int. Immunol. 16, 1355-1364 (2004).